Biologic Agents in the Treatment of Childhood-Onset Rheumatic Disease

J Pediatr. 2017 Oct:189:31-39. doi: 10.1016/j.jpeds.2017.06.041. Epub 2017 Jul 13.

Authors

Jay Mehta¹, Timothy Beukelman²

Affiliations

¹ Department of Pediatrics, Division of Rheumatology, Children's Hospital of Philadelphia, Philadelphia, PA.
² Department of Pediatrics, Division of Rheumatology, University of Alabama at Birmingham, Birmingham, AL. Electronic address: [email protected].

PMID: 28711176
DOI: 10.1016/j.jpeds.2017.06.041

No abstract available

MeSH terms

Abatacept / adverse effects
Abatacept / therapeutic use
Adalimumab / adverse effects
Adalimumab / therapeutic use
Adolescent
Antibodies, Monoclonal, Humanized / therapeutic use
Arthritis, Juvenile / diagnosis*
Arthritis, Juvenile / drug therapy*
Biological Factors / adverse effects*
Biological Factors / pharmacology
Biological Factors / therapeutic use*
Child
Etanercept / adverse effects
Etanercept / therapeutic use
Female
Humans
Male
Prognosis
Rheumatic Diseases / diagnosis
Rheumatic Diseases / drug therapy
Risk Assessment
Rituximab / adverse effects
Rituximab / therapeutic use
Severity of Illness Index
Treatment Outcome
United States
United States Food and Drug Administration

Substances

Antibodies, Monoclonal, Humanized
Biological Factors
Rituximab
Abatacept
Adalimumab
tocilizumab
Etanercept